Mechanistic Vs. Empirical Network Models of Drug Action

CPT: Pharmacometrics and Systems Pharmacology 09/2013; 2(9):e72. DOI: 10.1038/psp.2013.51
Source: PubMed


Declining success rates coupled with increased costs is leading to an inevitable breaking point in the drug development pipeline. Can we avoid it by incorporating the vast mechanistic understanding of drug action? A recent review highlights this dilemma and proposes “quantitative logic gate” modeling as a solution.1 The goal of this commentary is to contrast this approach with mechanistic biochemical network models, which, although alluded to by Kiruoac and Onsum, requires a closer analysis.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e72; doi:10.1038/psp.2013.51; advance online publication 6 September 2013


Available from: Marc Birtwistle, Jun 25, 2014
  • Source

    CPT: Pharmacometrics and Systems Pharmacology 03/2014; 3(3):e104. DOI:10.1038/psp.2014.4
  • [Show abstract] [Hide abstract]
    ABSTRACT: Advances in systems biology have allowed the development of a highly characterized systems pharmacology model to study mechanisms of drug-induced hepatotoxicity. In this issue of CPT, Yang et al. describe a model, DILIsym, used to characterize mechanisms of hepatotoxicity of troglitazone. Their modeling approach has provided new insight into troglitazone-induced hepatotoxicity in humans but is not associated with hepatotoxicity in rats, consistent with preclinical data for this drug.Clinical Pharmacology & Therapeutics (2014); 96 5, 536-537. doi:10.1038/clpt.2014.167
    Clinical Pharmacology &#38 Therapeutics 11/2014; 96(5):536-7. DOI:10.1038/clpt.2014.167 · 7.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Targeted therapies have become an important therapeutic paradigm for multiple malignancies. The rapid development of resistance to these therapies impedes the successful management of advanced cancer. Due to the redundancy in angiogenic signaling, alternative proangiogenic factors are activated upon treatment with anti-VEGF agents. Higher doses of the agents lead to greater stimulation of compensatory proangiogenic pathways that limit the therapeutic efficacy of VEGF-targeted drugs and produce escape mechanisms for tumor. Evidence suggests that dose intensity and schedules affect the dynamics of the development of this resistance. Thus, an optimal dosing regimen is crucial to maximizing the therapeutic benefit of antiangiogenic agents and limiting treatment resistance. A systems pharmacology approach using multiscale computational modeling can facilitate a mechanistic understanding of these dynamics of angiogenic biomarkers and their impacts on tumor reduction and resistance. Herein, we discuss a systems pharmacology approach integrating the biology of VEGF-targeted therapy resistance, including circulating biomarkers, and pharmacodynamics to enable the optimization of antiangiogenic therapy for therapeutic gains.
    Frontiers in Pharmacology 02/2015; 6:33. DOI:10.3389/fphar.2015.00033 · 3.80 Impact Factor
Show more